Bone development

P1 Abstract withdrawn

P2 Treatment of partial growth arrest using cylindrical costal osteochondral graft
Ryo Orito (Osaka, Japan)

P3 Abstract withdrawn

P4 Applicability of the Tanner-Whitehouse 3 method to United Kingdom children born in the 21st century
Khalaf Alshamrani (Sheffield, United Kingdom)

P5 Response of bone to mechanical stimulation in the offspring of MAVIDOS study mothers in a single centre; the effect of antenatal vitamin D supplementation.
Sujatha Gopal (Sheffield, United Kingdom)

P6 Pseudohypoparathyroidism type Ib initially masquerading as epileptic seizures due to Fahr´s disease
Stepan Kutilek (Pardubice, Czech Republic)

P7 Bone morphology patterns in children with osteogenesis imperfecta
Cathleen Raggio (New York, United States)

P8 Polyhydramnios: sole risk factor for non-traumatic fractures in two infants
Geneviève Nadeau (Montreal, Canada)

P9 Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study
Rachel L Duckham (Geelong, Australia)

P10 Radiographic evidence of zoledronic acid given during pregnancy – a case report
Amanda Peacock (Sheffield, United Kingdom)

P11 Reference values of cortical thickness, bone width, and Bone Health Index in metacarpals of children from age 0 y, as determined with an extension of the fully automated BoneXpert bone age method
Peter Thrane (Hørsholm, Denmark)

P12 Abstract withdrawn

P13 Clinical implications of modeling the maturational spurt
Melanie Boeyer (Missouri, United States)

P14 Bone health in children with congenital heart disease
Marta Erlandson (Saskatoon, Canada)

P15 TA-46 prevents premature synchondrosis and restores foramen magnum size in a mouse model of achondroplasia
Guylene Rignol (Nice, France)

P16 Higher neonatal bone mineral content and lower IL-6 levels in offspring of overweight/obese women following antenatal exercise: The IMPROVE randomized controlled trial (RCT)
Sumudu Nimali Seneviratne (Colombo, Sri Lanka)

P17 Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults
Tandy Aye (California, United States)

P18 Bone mass and fracture prevalence in Childhood Brain Cancer Survivors (CBCS) 2 or 5 years after off therapy
Natascia di Iorgi (Genova, Italy)

Bone fragility and metabolism

P19 Progresive-deforming form of osteogenesis imperfecta in neonates - own experience
Katarzyna Haladaj (Łódź, Poland)

P20 Abstract withdrawn

P21 Efficacy and safety of intravenous infusión of ibandronic acid in children with Osteogenesis Imperfecta
Shokery Awadalla (Bogota, Colombia)

P22 Tibia microarchitecture in children with recent fractures
Rebecca Moon (Southampton, United Kingdom)

P23 What happens to the skeleton at the time of diagnosis of paediatric cancer?
Artemis Doulgeraki (Athens, Greece)

P24 The role of the RACK1-c-Src axis in regulation of osteoclast function
Jin Hee Park (Seoul, South Korea)

P25 Short term mechanical stimulation using whole body vibration identifies differences in bone response between prepubertal boys with and without prior fracture
Rachel Harrison (Sheffield, United Kingdom)

P26 Parathyroid hormone is higher in infants with fracture as opposed to without fracture undergoing skeletal survey for suspected non-accidental injury, and is inversely associated with mean corpuscular haemoglobin content.
Nick Bishop (Sheffield, United Kingdom)

P27 Response to mechanical stimulation of bone in children with osteogenesis imperfecta and the effect of bisphosphonate therapy
Sivagamy Sithambaran (Sheffield, United Kingdom)

P28 Duchenne Muscular Dystrophy: preliminary results of the Risbo-DMD study

Francesca Broggi (Milano, Italy)

P29 Rib cage anomalies in a cohort of Osteogenesis Imperfecta patients
Lidiia Zhytnik (Tartu, Estonia)

P30 Bone mass, sclerostin and body composition in women with anorexia nervosa: a 3-year follow-up after weight gain therapy
Anna Svedlund (Gothenburg, Sweden)

P31 Determinants of survival in osteogenesis imperfecta (OI) Type II
Ruchi Nadar (Birmingham, United Kingdom)

P32 Successful use of oral acetazolamide in symptomatic subcutaneous calcifications in hyperphosphatemic tumoral calcinosis
Ruchi Nadar (Birmingham, United Kingdom)

P33 Unusual case of severe hypophosphataemic rickets and renal stones associated with valproate use
Donatella Pintus (Liverpool, United Kingdom)

P34 Bone metabolism and bone mineral density in Duchenne muscular dystrophy.
Joanna Bautembach-Minkowska (Gdansk, Poland)

P35 Atypical fractures in pediatric patients with osteogenesis imperfect treated with zoledronic acid
Alhelí Lucía Bremer (Mexico City, Mexico)

P36 ALPL gene mutation in a family
Silvia Vai (Milano, Italy)

P37 Generation of osteogenesis imperfecta type XIV zebrafish models
Laura Leoni (Pavia, Italy)

P38 Clinical features and approach to treatment in pediatric patients with McCune-Albright syndrome: monocentric experience.
Nadezhda Makazan (Moscow, Russian Federation)

P39 Bone health outcomes in children with Duchenne Muscular Dystrophy
Verene Chua (Sydney, Australia)

P40 Stature and body weight more than age explain functionality level in children with Osteogenesis Imperfecta
Ana De David (Brasilia, Brazil)

P41 Increased prevalence of fractures in poorly chelated children with beta thalassemia
Sonal Palande (Pune, India)

P42 FGF 23 measurements in children with fibrous dysplasia: useful or not?
Zilla Huma (London, United Kingdom)

P43 Bone health is compromised in adult patients with childhood-onset autoimmune-polyendocrinopathy-candiadis-ectodermal dystrophy (APECED)
Saila Laakso (Helsinki, Finland)

P44 Bone mass and vertebral fractures in South African (SA) children on prolonged oral glucocorticoids (GCs) for chronic non-malignant illnesses
Kebashni Thandrayen (Johannesburg, South Africa)

P45 Osteogenesis imperfecta type 15 with neurological phenotype associated with homozygous WNT1 mutation and uniparental isodisomy for chromosome 12
Belinda Crowe (London, United Kingdom)

P46 Vertebral fractures are more prevalent than long bone fractures in boys with glucocorticoid-treated Duchenne Muscular Dystrophy: Results of a prospective observational study
Stefan A Jackowski (Ottawa, Canada)

P47 Anorexia nervosa: weighing in on bone health surveillance
When should it be performed?
Mekhala Ayya (Birmingham, United Kingdom)

P48 Does improved genetic screening make it more difficult to diagnose osteogenesis imperfecta?
Eleanor Burke (Galway, Ireland)

Bone mineralisation disorders

P49 Bone mineral density and vitamin D status in children with chronic neurological syndromes - clinical observations
Elzbieta Jakubowska-Pietkiewicz (Lodz, Poland)

P50 Treatment with asfotase alfa for patients with infantile hypophosphatasia and screening plan of hypophosphatasia by low ALP level and dental findings in Korea
Sungyoon Cho (Seoul, South Korea)

P51 Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia
Volha V Zhukouskaya (Le Kremlin Bicêtre, France)

P52 Variable familial expression of spondylometaphyseal dysplasia with coxa vara and a novel FN1 mutation
Elisabeth Steichen-Gersdorf (Innsbruck, Austria)

P53 Successful treatment with enzyme replacement therapy in a girl with severe infantile Hypophosphatasia
Katrin Heldt (St.Gallen, Switzerland)

P54 Is oral health correlated with skeletal phenotype in primary metabolic bone diseases? A preliminary report of the Greek experience
Artemis Doulgeraki (Athens, Greece)

P55 Abstract withdrawn

P56 Unusual cause of abdominal pain in adolescent girl
Milan Bayer (Prague, Czech Republic)

P57 Effective therapy with growth hormone of an adolescent patient with growth hormone deficiency and osteopetrosis. A case report
Elpis Athina Vlachopapadopoulou (Athens, Greece)

P58 The validity of serum alkaline phosphatase to identify nutritional rickets in Nigerian children on a calcium-deprived diet
Tom Thacher (Rochester, United States)

P59 Effective treatment of a patient with hypophosphatemic rickets leading to normal adult height
Elpis Athina Vlachopapadopoulou (Athens, Greece)

P60 FGF23-expressing osteocytes are confined to bone packets that completed primary mineralization in patients with chronic kidney disease on dialysis (CKD5D)
Nadja Fratzl-Zelman (Vienna, Austria)

P61 Biochemical and genetic analysis in patients with odontohypophosphatasia in Japan
Takuo Kubota (Suita, Japan)

P62 Tissue non-specific alkaline phosphatase activity and mineralization capacity of bi-allelic mutations from severe perinatal and asymptomatic hypophosphatasia phenotypes: Results from an in-vitro mutagenesis model
Suma Uday (Birmingham, United Kingdom)

P63 Bone geometry and microarchitecture deficits in children with Alagille Syndrome
Joseph Kindler (Philadelphia, United States)

P64 Missense mutations in ENPP1 result in osteoporosis in patients and is recapitulated in the ENPP1 loss of function murine model
Demetrios Braddock (New Haven, United States)

P65 Tumor induced osteomalacia in a 12-year-old girl: Case report
Voraluck Phatarakijnirund (Bangkok, Thailand)

P66 Bone densitometry and body composition in children with hypophosphatasia
William Mciver (Birmingham, United Kingdom)

P67 Bone health outcomes in children and adolescents with neuromuscular disease
Andrew Biggin (Westmead, Australia)

P68 Clinical case of a child with a hereditary vitamin D dependent rickets type 1a, complicated by rachitic lung and oxygen dependence
Nina Polyakova (Moscow, Russian Federation)

P69 Experience of implementation and monitoring of burosumab treatment in a multi-disciplinary setting

Caroline Marr (Sheffield, United Kingdom)

P70 Metabolic bone disease of prematurity – comparing neonatal and endocrine approaches using a nationwide survey
Amish Chinoy (Manchester, United Kingdom)

P71 Necessity of high dose and prolonged duration denosumab post stem cell transplant for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis
Tashunka Taylor-Miller (Bristol, United Kingdom)

P72 Burosumab experience in UK X-linked hypophosphataemia children under five years old
Poonam Dharmaraj (Liverpool, United Kingdom)

P73 Burosumab initiation in a UK X-linked hypophosphataemia cohort: real-world use resonates with research evidence
Poonam Dharmaraj (Liverpool, United Kingdom)

P74 Burosumab can improve pain and quality of life for children with X-linked hypophosphataemia and their families: a London centre's experience
Robyn Gilbey-Cross (London, United Kingdom)

P75 Active vitamin D analogues and oral phosphate for the treatment of X-linked hypophosphataemia in paediatric patients: A systematic literature review and survey of expert opinion on current needs.
Zulf Mughal (Manchester, United Kingdom)

P76 Safety profile of asfotase alfa treatment of patients with hypophosphatasia: a pooled analysis
Michael P. Whyte (Saint Louis, United States)

P77 Long-term efficacy profile of asfotase alfa in the treatment of patients with hypophosphatasia: a pooled analysis
Michael P. Whyte (Saint Louis, United States)

P78 Abstract withdrawn

P79 Novel imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
Adalbert Raimann (Vienna, Austria)

P80 Characterization of pain in patients with fibrous dysplasia
Tiahna Spencer (Bethesda, United States)

P81 Bone health in adolescent females with anorexia nervosa may be preserved by high lean mass
Munier Nour (Saskatoon, Canada)

P82 Tertiary hyperparathyroidism and post-operative hungry bone syndrome in a patient with X-linked hypophosphatemic rickets
Munier Nour (Saskatoon, Canada)

Diagnostics and imaging

P83 Could digital X-ray radiogrammetry be an alternative for dual energy X-ray absorptiometry
Jos Draaisma (Nijmegen, Netherlands)

P84 Abstract withdrawn

P85 Neonatal calcinosis cutis due to a mutation in the GNAS gene
Yael Levy-Shraga (Ramat-Gan, Israel)

P86 Disease-specific pathological traits of youth at risk of secondary osteoporosis as determined through peripheral quantitative computed tomography
Paola Chivers (Fremantle, Australia)

P87 Assessment of bone density by DXA in poorly controlled children with β-Thalassemia: Correction for hepatic iron -overloadby manual analysis
Sonal Palande (Pune, India)

P88 Diagnostic performance of morphometric vertebral fracture analysis (MXA) in children using a 33-point software programme
Fawaz Alqahtani (Sheffield, United Kingdom)

P89 Use of DXA and pQCT measurements to screen for fracture risk in 3 to 18 year old poorly chelated thalassaemic children.
Sonal Palande (Pune, India)

P90 Osteogenesis imperfecta due to FKBP10 mutation- shift from high to low bone turnover
Nina Lenherr-Taube (Toronto, Canada)

P91 Bone health index by hand X-ray compared with bone mineral density by dual-energy X-ray absorptiometry in children with Duchenne muscular dystrophy
Sasigarn A Bowden (Columbus, United States)

P92 A little girl with bowing of legs, a short mother and a waddling sister: Metaphyseal Chondrodysplasia, Schmid Type
Sumudu Nimali Seneviratne (Colombo, Sri Lanka)

P93 Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children
David Fennimore (Sheffield, United Kingdom)

P94 Characteristics of ultradistal radius bone density during childhood: Results from the Bone Mineral Density in Childhood Study
Joseph Kindler (Philadelphia, United States)

P95 Detection of intact FGF23 using a novel well-characterized ELISA
Annegret Bitzer (Vienna, Austria)

P96 Radiofrequency echographic multispectrometry (REMS): a new approach for osteoporosis diagnosis in adolescents
Carla Caffarelli (Siena, Italy)

P97 Association of serum alkaline phosphatase with radiological rickets severity in children with X-linked hypophosphataemia on conventional therapy
Suma Uday (Birmingham, United Kingdom)

P98 The effect of vitamin D on bone health assessed by radiogrammetry: a double-blind placebo-controlled vitamin D supplementation trial in infants
Suma Uday (Birmingham, United Kingdom)

P99 Pre and post-natal achondroplasia, retrospective series of 64 consecutives cases with analyze of the diagnostic methods and timing issues
Genevieve Baujat (Paris, France)

P100 High-resolution MRI assessment of the muscle-fat-bone unit in young adults with childhood onset Crohn's disease
Lewis Steell (Glasgow, United Kingdom)

Epidemiology

P101 Vitamin D levels among Lebanese children: Do we need to alter normal level?
Yasser Yaghi (Saida, Lebanon)

P102 Vitamin D deficiency in children in Israel: a cross-sectional study and possible associated factors
Gerard Korchia (Jerusalem, Israel)

P103 Abstract withdrawn

P104 Vitamin D deficiency nutritional rickets presenting to secondary care in children (<16 Years) – A United Kingdom surveillance study
Nick Shaw (Birmingham, United Kingdom)

P105 Respiratory health impacts quality of life for adults with OI
Cathleen Raggio (New York, United States)

P106 Scoliosis and cardiopulmonary outcomes in adults with osteogenesis imperfecta: A pilot study
Cathleen Raggio (New York, United States)

P107 Sex differences in the longitudinal associations between body composition and bone stiffness index in European children and adolescents
Lan Cheng (Bremen, Germany)

P108 Abstract withdrawn

P109 Fracture prevalence in children 0-19 years-old in Mexico: A 10-year cross-sectional analysis
Patricia Clark (Mexico City, Mexico)

P110 Cost-effectiveness of a Vitamin D supplementation programme in pregnant women and children to prevent rickets in the UK
Raja Padidela (Manchester, United Kingdom)

Genetics

P111 Vitamin D dependent rickets type 1 caused by CYP27B1 mutation
Chan Jong Kim (Gwangju, South Korea)

P112 Case report: investigation of an osteolytic lesion leading to the diagnosis of congenital generalized lipodystrophy due to a novel AGPAT2 mutation
Avivit Brener (Tel Aviv, Israel)

P113 Next-generation sequence and biomarker levels in the patients with early-onset chronic non-bacterial osteomyelitis from North Caucasian region of Russia
Mikhail Kostik (St Petersburg, Russian Federation)

P114 Hypophosphatasia in Japan: ALPL mutation analysis in 98 patients
Toshimi Michigami (Izumi, Japan)

P115 Mabry Syndrome is a cause of hyperphosphatasia and mental retardation
Talat Mushtaq (Leeds, United Kingdom)

P116 Molecular genetic diagnosis and genotype-phenotype correlations in children and adolescents with recurrent fractures
Jessica del Gigante (Westmead, Australia)

P117 Use of Lego® to explain genetic variations in Type 1 collagen – a pilot study
Jeremy Allgrove (London, United Kingdom)

P118 Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome
Carla Caffarelli (Siena, Italy)

P119 A novel mutation in FAM111A gene in child with Kenny-Caffey syndrome type 2 presenting with short statue, medullary stenosis and hypoparathyroidism.
Khomsak Srilanchakon (Bangkok, Thailand)

P120 Mutational and phenotypic spectra in 137 Russian patients with inherited forms of rickets
Kristina Kulikova (Moscow, Russian Federation)

P121 An Acvr1[R258G] "conditional on" mouse model of atypical fibrodysplasia ossificans progressiva (FOP) is Activin A dependent
Sarah Hatsell (Tarrytown, United States)

P122 Congenital hyperinsulinism of infancy in a child with autosomal dominant hypocalcaemia type 1 due to an activating calcium sensing receptor mutation
Evelien Gevers (London, United Kingdom)

P123 Odontochondrodysplasia in association with a TRIP11 mutation
Sabrina Sheridan (Dublin, Ireland)

P124 Heterozygous CDC73 mutation causing parathyroid adenoma in an adolescent girl presenting with mental health issues
Ian Mulvey (Liverpool, United Kingdom)

P125 SCN8a mutations and osteoporosis. Is osteocyte dysfunction the cause or the consequence?
Gillian O'Donnell (Dublin, Ireland)

Medical therapies

P126 Anemia - novel clinically significant finding during intravenous pamidronate therapy of children diagnosed with osteogenesis imperfecta.
Izabela Michalus (Lodz, Poland)

P127 Burosumab therapy in pediatric patients with X-linked hypophosphatemia improves body composition
Avivit Brener (Tel Aviv, Israel)

P128 Growth hormone effect on bone mineral density in a girl with osteogenesis imperfecta – a case presentation
Sofia Leka (Athens, Greece)

P129 A smartphone based survey of frequency and severity of adverse effects following bisphosphonate therapy in a tertiary paediatric centre
James Blackburn (Liverpool, United Kingdom)

P130 Off label uses of pamidronate in rare pediatric bone diseases (Jansen's metaphyseal chondrodysplasia and generalized arterial calcification of infancy): A four year perspective
Kyleen Young (Chicago, United States)

P131 Use of intravenous pamidronate in pediatric acute lymphoblastic leukemia patients with osteonecrosis (ON) results in reduced pain and improved radiologic outcome of ON lesions: Long- term follow-up over 15-years
Paivi Miettunen (Calgary, Canada)

P132 A prospective study of 17 consecutive pediatric patients with chronic non-bacterial osteomyelitis treated with intravenous pamidronate over a 15 year period at a single center reveals excellent clinical and radiologic outcome initially and after flare
Paivi Miettunen (Calgary, Canada)

P133 Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse
Nick Bishop (Sheffield, United Kingdom)

P134 First report of skin reaction with zoledronic acid
Patricia Olivier (Montreal, Canada)

P135 Oral ibandronate therapy in patients with osteogenesis imperfecta
Stephan Kutilek (Klatovy, Czech Republic)

P136 Intravenous bisphosphonate treatment in severe infantile hypercalcemia associated with Williams Syndrome
Alissa M. Guarneri (Columbus, United States)

P137 Reversion to pamidronate after switch to zoledronic acid in children with bone disease
Amanda Peacock (Sheffield, United Kingdom)

P138 How early is early enough – bisphosphonate treatment in osteogenesis imperfecta
Heike Hoyer-Kuhn (Cologne, Germany)

P139 Growth hormone therapy in a child with severe short stature due to Miller-McKusick-Malvaux (3M) syndrome-2
Sumudu Nimali Seneviratne (Colombo, Sri Lanka)

P140 Safety and effectiveness of stoss therapy in children
Melissa Fiscaletti (Montreal, Canada)

P141 Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population
Christie-Lee Wall (Westmead, Australia)

P142 Protocol: A randomized trial of zoledronate in children with cerebral palsy
Jakob Bie Granild-Jensen (Randers, Denmark)

P143 Intermittent bi-daily sub-cutaneous teriparatide infusion in children with hypoparathyroidism: a single-centre experience
Sacha Flammier (Lyon, France)

P144 A multi-criteria decision analysis of the value of burosumab for the treatment of paediatric patients with X-linked hypophosphatemia in Portugal
Ines Alves (Èvora, Portugal)

P145 Nine-month follow-up data on biochemical, clinical, radiological and functional parameters in a clinical cohort of children at Evelina London Children's Hospital with X-linked hypophosphataemia treated with burosumab
Jessica L. Sandy (London, United Kingdom)

P146 Does prior bisphosphonate therapy in children and adolescents with cerebral palsy alter surgical outcomes?
Melissa Fiscaletti (Montreal, Canada)

P147 Changes in DXA Z-scores during bisphosphonate (BP) therapy in patients with osteogenesis imperfecta (OI) at a tertiary care hospital in South Africa
Kebashni Thandrayen (Johannesburg, South Africa)

P148 Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression
William Singleton (Bristol, United Kingdom)

P149 Bone mineral changes in 43 children with osteogenesis imperfecta treated by pamidronate.
Mikhail Kostik (St Petersburg, Russian Federation)

P150 Osteogenesis imperfecta: Skeletal outcomes after bisphosphonates Discontinuation at Final Height
Marie-Eve Robinson (Montreal, Canada)

P151 The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: A randomized controlled pilot trial
Marie-Eve Robinson (Montreal, Canada)

P152 An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis
Marie-Eve Robinson (Montreal, Canada)

P153 Long-term growth hormone treatment alters glucose metabolism in achondroplasia
Daisuke Harada (Osaka, Japan)

Muscle and bone

P154 Self-reported sedentary time is negatively associated with microarchitecture of the tibia
Rebecca Moon (Southampton, United Kingdom)

P155 Gender specific paediatric reference data for muscle function parameters assessed using jumping mechanography
Sonal Palande (Pune, India)

P156 Patients with nephropatic cystinosis display lower cortical thickness and grip strength
Susanne Bechtold-Dalla Pozza (Munich, Germany)

P157 Gonadotrophin releasing hormone analogues utilised in late and post-pubertal adolescents causes a reduction in bone density in transgender teenagers attending a national gender dysphoria clinic
Talat Mushtaq (Leeds, United Kingdom)

P158 Association of grip strength and body composition in Indian boys and girls
Sonal Palande (Pune, India)

P159 Determinants of muscle function in 6 to 11 year old rural Indian children
Sonal Palande (Pune, India)

P160 Assessment of muscle mass and function in Indian children with Type 1 diabetes

Sonal Palande (Pune, India)

P161 Endocrinological complications in Czech paediatric patients with Duchenne muscular dystrophy
Marie Sediva (Prague, Czech Republic)

P162 Bone monitoring and morbidity in adults with Duchenne muscular dystrophy: Challenges in implementation of standards of care
Sze Choong Wong (Glasgow, United Kingdom)

P163 Prenatal oligohydramnios is associated with hip shape in adolescent males
Alex Ireland (Manchester, United Kingdom)

P164 Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn's disease: Results of a prospective, observational inception cohort study
Stefan A Jackowski (Ottawa, Canada)

Nutrition

P165 Fibroblast growth factor-21 (FGF-21) – marker of mineral bone disorder
Lubica Ticha (Bratislava, Slovakia)

P166 The ketogenic diet and bone density: a retrospective longitudinal cohort study
Jos Draaisma (Nijmegen, Netherlands)

P167 Children's multivitamins do not contain sufficient vitamin D
Rebecca Moon (Southampton, United Kingdom)

P168 Milk derived anti-osteoporotic peptide checks negative effect of miR-592 on osteogenesis
Taruneet Kaur (Karnal, India)

P169 Rescue diet restores bone matrix mineralization in mice with a non-functioning vitamin D receptor
Barbara Misof (Vienna, Austria)

P170 Serum 25-hydroxyvitamin D requirements to prevent rickets in Nigerian children on a calcium-deprived diet
Tom Thacher (Rochester, United States)

P171 Seasonal Variations in Vitamin D Status in Children with Haematological Malignancies in Sweden
Natalja Jackmann (Uppsala, Sweden)

P172 Cow's milk allergic infants on amino acid-based medical nutrition formula maintain adequate serum concentrations of phosphorus, calcium and magnesium despite the use of acid-suppressive medication
Simone Eussen (Utrecht, Netherlands)

P173 Motor and nutritional aspects of individuals with osteogenesis imperfecta assisted in Brazilian midwest region
Giovana Ceolho (Brasilia, Brazil)

P174 Supplementation of children with type 1 diabetes with milk or pharmacological calcium for improving bone health- A randomized controlled trial
Sonal Palande (Pune, India)

P175 Dietary behaviours and compromised nutritional intakes in children with Osteogenesis Imperfecta
Lisa Mills (Bristol, United Kingdom)

P176 Prevalence of vitamin D deficiency in newly diagnosed children with cancer
Heidi Kecskemethy (Wilmington, United States)

Orthopaedics and physical activity

P177 Feasibility of a 13-week targeted exercise intervention on tibial bone mineral density in adolescents with Developmental Coordination Disorder
Jocely Tan (Fremantle, Australia)

P178 The role of hydrotherapy in the management of children with severe Osteogenesis Imperfecta
Emilie Hupin (London, United Kingdom)

P179 Clinical and radiological characteristics of children`s forearm deformations with hereditary multiple exostosis (clinical observation)
Ekaterina Belousova (St. Petersburg, Russian Federation)

P180 A retrospective review of modern spine surgery in the skeletal dysplasia population
Cathleen Raggio (New York, United States)

P181 Walking quality of children with healed Perthes disease
Verity Pacey (North Ryde, Australia)

P182 Handgrip strength as functionality and independence indicative in osteogenesis imperfecta
Livia Luiz (Brasilia, Brazil)

P183 Functional outcomes of an adult with osteogenesis imperfecta after rehabilitation post-bilateral Girdlestone procedure: a case report
Joycie Eulah Abiera (Manila, Philippines)

P184 Material based on bioactive glass to replace bone defects in children after removal of tumors
Volodymyr Protsenko (Kiev, Ukraine)

P185 High impact exercise to improve musculoskeletal outcomes in Crohn's disease: a feasibility questionnaire
Lewis Steell (Glasgow, United Kingdom)

P186 Severe osteoporosis with life threatening vertebral fractures in a 15-years-old boy with juvenile idiopathic arthritis: a successful spinal cord decompression and posterior spinal fusion Th2-Th12
Jerzy Konstantynowicz (Bialystok, Poland)

Other

P187 Increased prevalence of overweight and obesity and its clinical predictors in children affected by X-linked hypophosphatemia
Volha V Zhukouskaya (Le Kremline Bicetre, France)

P188 Impact of type 1 diabetes mellitus on skeletal integrity and strength in adolescents aged 12 to 16 years; as assessed by High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
Janani Devaraja (Sheffield, United Kingdom)

P189 Cleidocranial dysplasia: A patient with severe dental phenotype
Artemis Doulgeraki (Athens, Greece)

P190 Cone-shaped epiphyses involving the knees: report of a case and differential diagnosis.
Artemis Doulgeraki (Athens, Greece)

P191 Supporting the emotional well-being of children living with osteogenesis imperfecta; an upstream health promotion initiative
Ali Seasman (Sheffield, United Kingdom)

P192 Developing a high chair to meet the needs of infants with Achondroplasia; a collaboration between Evelina London Children's Hospital and Brunel University.
Jill Massey (London, United Kingdom)

P193 Double trouble: A case of Trisomy 21 and achondroplasia
Stacey Todd (Glasgow, United Kingdom)

P194 Skeletal dysplasia in Saul Wilson Syndrome
Merete Ljungberg (Copenhagen, Denmark)

P195 Growth velocity measured by biomarker, COLX, in achondroplasia
Hanne Hove (Copenhagen, Denmark)

P196 Sleep related problems in children with osteogenesis imperfecta
Kieran Murphy (Sheffield, United Kingdom)

P197 A playful type of intervention for infants with osteogenesis imperfecta
Rebecca Jones (Sheffield, United Kingdom)

P198 The Multidisciplinary Team (MDT) Approach : What does it look like and why does it matter? An illustration of a true MDT approach to provide holistic care for a child with severe and complex osteogenesis imperfecta.
Rebecca Jones (Sheffield, United Kingdom)

P199 Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta
Richard McGee (Westmead, Australia)

P200 Whole body vibration training for children and adolescents with congenital myopathy
Verity Pacey (North Ryde, Australia)

P201 Juvenile dermatomyositis (JDM) and hypoparathyroidism (HP) in an adolescent girl
Jennifer Miller (Chicago, United States)

P202 Vibration therapy improves mobility and has no detrimental impact on bone health in adolescents with mild cerebral palsy independent of daily protocol duration (9 minutes/day vs. 15 minutes/day)
Silmara Gusso (Auckland, New Zealand)

P203 Side- alternating vibration training improves mobility and has no detrimental impact on bone health in young children with mild-moderate cerebral palsy.
Silmara Gusso (Auckland, New Zealand)

P204 A qualitative analysis of the burden-of-illness associated with X-linked hypophosphataemia (XLH) in children and adolescents
Nermina Ferizovic (Cambridge, United Kingdom)

P205 Bone mineral density in surgical hemivertebrae treatment in a prematurely born child – a case study
Dragana Vukliš (Novi Sad, Serbia)

P206 Robot-assisted exercises in children with cerebral palsy – A case study
Rastislava Krasnik (Novi Sad, Serbia)

P207 Group exercises aimed at poor body posture correction assisted by humanoid robot – A case study
Dragana Vukliš (Novi Sad, Serbia)

P208 Motor developmental outcomes in 2 babies with very severe osteogenesis imperfecta (type II)
Claire Sweeney (Birmingham, United Kingdom)

P209 Persistently low trabecular bone mineral density and normal bone strength at the radius over 3 years after simultaneous pancreas kidney transplantation
Ondrej Soucek (Prague, Czech Republic)

P210 Premature Physeal closure following 13 -cis - retinoic acid administration in neuroblastoma
Rashida Farhad Vasanwala (Singapore, Singapore)

P211 Value of osteogenesis imperfecta clinical nurse specialists to families and consultants across five UK centres
Mark Heathfield (London, United Kingdom)

P212 Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model
Kalyan Nannuru (Tarrytown, United States)

P213 Evaluating a therapy-led school and nursery outreach service for children with Osteogenesis Imperfecta
Alex Bultitude (London, United Kingdom)

P214 Assessment of multidisciplinary care of children with osteogenesis imperfecta at The Royal Manchester Children's Hospital
Paula Galloway (Manchester, United Kingdom)

P215 Evaluating the natural history of subcutaneous fat necrosis
Maria-Elena Lautatzis (Toronto, Canada)

P216 Dual diagnosis of autism and osteogenesis imperfecta: Case examples to illustrate the implications of dual diagnosis for enhanced outcomes for child and family
Rebecca Jones (Sheffield, United Kingdom)

P217 Abstract withdrawn

P218 Hypercalcemia and parathyroid hormone-related peptide expression in a 3 months old boy with colon hemangioendothelioma
Kelly Maury (Buenos Aires, Argentina)

P219 Comparison of cell separation methods, using relative expression of specific growth plate zone markers in a pig model.
Alireza Javanmardi (Vienna, Austria)

P220 New perspectives in diagnosis and management of optic neuropathy in fibrous dysplasia: utility of optical coherence tomography and computed tomography measurements
Kristen Pan (Bethesda, United Kingdom)

P221 Speech and hearing impairment and respiratory complications in a large cohort of patients with achondroplasia
Alessandra Cocca (London, United Kingdom)

P222 Long-term clinical outcome in chronic recurrent multifocal osteomyelitis (CRMO): the Leiden cohort
Ashna Ramautar (Leiden, Netherlands)

P223 A preliminary data of a prospective study on Iranian patients with osteogenesis imperfecta
Mina Ebrahim-Rad (Tehran, Iran)

P224 A teenager with recurrent fractures and multiple bone lesions, a diagnostic challenge
Sumudu Nimali Seneviratne (Colombo, Sri Lanka)

P225 A short girl with severe scoliosis and osteoporosis
Sumudu Nimali Seneviratne (Colombo, Sri Lanka)

P226 The case of normo-phosphatemic tumoral calcinosis treated with interleukine-1 inhibition (canakinumab)
Mikhail Kostik (St Petersburg, Russian Federation)

Late breaking abstracts

LB3 CD64: an adjunct to Kocher's criteria to differentiate septic arthritis and transient synovitis in children
Ajai Singh (Lucknow, India)

LB4 Impact of pubertal suppression on body composition and bone density in adolescents with gender dysphoria
Sheila Shepherd (Glasgow, United Kingdom)

LB5 Chronic recurrent multifocal osteomyelitis in children with hypophosphatasia explained by anti-inflammatory nucleotidase activity of tissue nonspecific alkaline phosphatase in mesenchymal and hematopoietic cells
David Magne (Villeurbanne, France)

LB6 Abstract withdrawn

LB7 Validation study of automated bone age assessment in 1285 children and adolescents aged 5 to 16 years
Klara Maratova (Prague, Czech Republic)

LB8 Nutritional status and bone mineral density in children with epidermolysis bullosa
Nataliya Balatska (Kiev, Ukraine)

LB9 Monitoring skull base abnormalities in children with osteogenesis imperfecta
Amaka Offiah (Sheffield, United Kingdom)

LB10 Foramen magnum stenosis (FMS):neuroradiological aspects before and after cervical decompression in paediatric patients with achondroplasia (ACH)
Anna Elsa Maria Allegri (Genova, Italy)